{"id":742088,"date":"2011-09-28T15:10:00","date_gmt":"2011-09-28T15:10:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-sells-its-interest-in-johnson-johnson-merck-consumer-pharmaceuticals\/"},"modified":"2026-08-10T13:01:16","modified_gmt":"2026-08-10T17:01:16","slug":"merck-sells-its-interest-in-johnson-johnson-merck-consumer-pharmaceuticals","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-sells-its-interest-in-johnson-johnson-merck-consumer-pharmaceuticals\/","title":{"rendered":"Merck Sells Its Interest in Johnson &amp; Johnson-Merck Consumer Pharmaceuticals"},"content":{"rendered":"<p>WHITEHOUSE STATION, N.J.&#8211;(BUSINESS WIRE)&#8211;Merck (NYSE:MRK), known outside the United States and Canada as MSD,        today announced that the company has sold its 50 percent interest in the        Johnson &amp; Johnson&#8211;Merck Consumer Pharmaceuticals Co. joint venture        (JJMCP) to Johnson &amp; Johnson (J&amp;J) affiliates, McNEIL-PPC, Inc., McNEIL        MMP, LLC, and Johnson &amp; Johnson, Inc. The venture between Merck and J&amp;J        was formed in 1989 to develop, manufacture, market and distribute        certain over-the-counter (OTC) consumer products in the United States        (U.S.) and Canada.     <\/p>\n<p>       Merck decided to sell its interest in the joint venture to enable the        company to fully focus on building the long-term growth prospects of the        wholly-owned consumer products division that had been part of        Schering-Plough Inc. prior to the 2009 merger. Under the agreement,        Merck will receive a one-time payment of $175 million. Merck&#8217;s rights to        the Pepcid brand outside the U.S. and Canada are not affected by this        transaction. Termination of the JJMCP venture also gives Merck greater        freedom to operate in the OTC consumer sector, allowing Merck to fully        exploit its pipeline of Rx-to-OTC switches as well as actively pursue        OTC licensing activities in the U.S. and Canada.     <\/p>\n<p>       Following the transaction, J&amp;J will own the venture&#8217;s assets which        include the exclusive rights to market OTC Pepcid, Mylanta, Mylicon and        other local OTC brands where they are currently sold in the U.S. and        Canada. The partnership assets include a manufacturing facility in        Lancaster, PA.     <\/p>\n<p>       <b>About Merck<\/b>     <\/p>\n<p>       Today&#8217;s Merck is a global healthcare leader working to help the world be        well. Merck is known as MSD outside the United States and Canada.        Through our prescription medicines, vaccines, biologic therapies, and        consumer care and animal health products, we work with customers and        operate in more than 140 countries to deliver innovative health        solutions. We also demonstrate our commitment to increasing access to        healthcare through far-reaching policies, programs and partnerships. For        more information, visit <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com%2F&amp;esheet=50011515&amp;lan=en-US&amp;anchor=www.merck.com&amp;index=1&amp;md5=88c77f328216eeab13a860f002314544\">www.merck.com<\/a>        and connect with us on Twitter, Facebook and YouTube.     <\/p>\n<p>       <b>Forward-Looking Statement<\/b>     <\/p>\n<p>       This news release includes \u201cforward-looking statements\u201d within the        meaning of the safe harbor provisions of the United States Private        Securities Litigation Reform Act of 1995. Such statements may include,        but are not limited to, statements about the benefits of the merger        between Merck and Schering-Plough, including future financial and        operating results, the combined company\u2019s plans, objectives,        expectations and intentions and other statements that are not historical        facts. Such statements are based upon the current beliefs and        expectations of Merck\u2019s management and are subject to significant risks        and uncertainties. Actual results may differ from those set forth in the        forward-looking statements.     <\/p>\n<p>       The following factors, among others, could cause actual results to        differ from those set forth in the forward-looking statements: the        possibility that the expected synergies from the merger of Merck and        Schering-Plough will not be realized, or will not be realized within the        expected time period; the impact of pharmaceutical industry regulation        and health care legislation; the risk that the businesses will not be        integrated successfully; disruption from the merger making it more        difficult to maintain business and operational relationships; Merck\u2019s        ability to accurately predict future market conditions; dependence on        the effectiveness of Merck\u2019s patents and other protections for        innovative products; the risk of new and changing regulation and health        policies in the U.S. and internationally and the exposure to litigation        and\/or regulatory actions.     <\/p>\n<p>       Merck undertakes no obligation to publicly update any forward-looking        statement, whether as a result of new information, future events or        otherwise. Additional factors that could cause results to differ        materially from those described in the forward-looking statements can be        found in Merck\u2019s 2010 Annual Report on Form 10-K and the company\u2019s other        filings with the Securities and Exchange Commission (SEC) available at        the SEC\u2019s Internet site (<a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=50011515&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=2&amp;md5=bff4d4e672f90be508d50c9bcbc173af\">www.sec.gov<\/a>).     <\/p>\n<\/p>\n<p><p>       Merck<br \/>Media Contact:<br \/>Amy Rose, 908-473-5161<br \/>or<br \/>Investor        Contact:<br \/>Carol Ferguson, 908-423-4465     <\/p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known outside the United States and Canada as MSD, today announced that the company has sold its 50 percent interest in the Johnson &amp; Johnson-Merck Consumer Pharmaceuticals Co. joint venture (JJMCP) to Johnson &amp; Johnson (J&amp;J) affiliates, McNEIL-PPC, Inc., McNEIL MMP, LLC, and Johnson &amp; Johnson, Inc. The venture between Merck and J&amp;J was formed in 1989 to develop, manufacture, market and distribute certain over-the-counter (OTC) consumer products in the United States (U.S.) and Canada. Merck decided to sell its interest in the joint venture to enable the company to fully focus on building the long-term growth prospects of the wholly-owned consumer products division that had been part of Schering-Plough Inc. prior to the 2009 merger. Under the agreement, Merck will receive a one-time payment of $175 million. Merck&#8217;s rights to the Pepcid brand outside the U.S. and Canada are not affected by this transaction. Termination of the JJMCP venture also gives Merck greater<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289],"class_list":["post-742088","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Sells Its Interest in Johnson &amp; Johnson-Merck Consumer Pharmaceuticals - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-sells-its-interest-in-johnson-johnson-merck-consumer-pharmaceuticals\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Sells Its Interest in Johnson &amp; Johnson-Merck Consumer Pharmaceuticals - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known outside the United States and Canada as MSD, today announced that the company has sold its 50 percent interest in the Johnson &amp; Johnson-Merck Consumer Pharmaceuticals Co. joint venture (JJMCP) to Johnson &amp; Johnson (J&amp;J) affiliates, McNEIL-PPC, Inc., McNEIL MMP, LLC, and Johnson &amp; Johnson, Inc. The venture between Merck and J&amp;J was formed in 1989 to develop, manufacture, market and distribute certain over-the-counter (OTC) consumer products in the United States (U.S.) and Canada. Merck decided to sell its interest in the joint venture to enable the company to fully focus on building the long-term growth prospects of the wholly-owned consumer products division that had been part of Schering-Plough Inc. prior to the 2009 merger. Under the agreement, Merck will receive a one-time payment of $175 million. Merck&#039;s rights to the Pepcid brand outside the U.S. and Canada are not affected by this transaction. Termination of the JJMCP venture also gives Merck greater\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-sells-its-interest-in-johnson-johnson-merck-consumer-pharmaceuticals\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-10T17:01:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-sells-its-interest-in-johnson-johnson-merck-consumer-pharmaceuticals\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-sells-its-interest-in-johnson-johnson-merck-consumer-pharmaceuticals\\\/\",\"name\":\"Merck Sells Its Interest in Johnson &amp; Johnson-Merck Consumer Pharmaceuticals - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2011-09-28T15:10:00+00:00\",\"dateModified\":\"2026-08-10T17:01:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-sells-its-interest-in-johnson-johnson-merck-consumer-pharmaceuticals\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-sells-its-interest-in-johnson-johnson-merck-consumer-pharmaceuticals\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-sells-its-interest-in-johnson-johnson-merck-consumer-pharmaceuticals\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Sells Its Interest in Johnson &#038; Johnson-Merck Consumer Pharmaceuticals\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Sells Its Interest in Johnson &amp; Johnson-Merck Consumer Pharmaceuticals - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-sells-its-interest-in-johnson-johnson-merck-consumer-pharmaceuticals\/","og_locale":"en_US","og_type":"article","og_title":"Merck Sells Its Interest in Johnson &amp; Johnson-Merck Consumer Pharmaceuticals - Merck.com","og_description":"Merck (NYSE:MRK), known outside the United States and Canada as MSD, today announced that the company has sold its 50 percent interest in the Johnson &amp; Johnson-Merck Consumer Pharmaceuticals Co. joint venture (JJMCP) to Johnson &amp; Johnson (J&amp;J) affiliates, McNEIL-PPC, Inc., McNEIL MMP, LLC, and Johnson &amp; Johnson, Inc. The venture between Merck and J&amp;J was formed in 1989 to develop, manufacture, market and distribute certain over-the-counter (OTC) consumer products in the United States (U.S.) and Canada. Merck decided to sell its interest in the joint venture to enable the company to fully focus on building the long-term growth prospects of the wholly-owned consumer products division that had been part of Schering-Plough Inc. prior to the 2009 merger. Under the agreement, Merck will receive a one-time payment of $175 million. Merck's rights to the Pepcid brand outside the U.S. and Canada are not affected by this transaction. Termination of the JJMCP venture also gives Merck greater","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-sells-its-interest-in-johnson-johnson-merck-consumer-pharmaceuticals\/","og_site_name":"Merck.com","article_modified_time":"2026-08-10T17:01:16+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-sells-its-interest-in-johnson-johnson-merck-consumer-pharmaceuticals\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-sells-its-interest-in-johnson-johnson-merck-consumer-pharmaceuticals\/","name":"Merck Sells Its Interest in Johnson &amp; Johnson-Merck Consumer Pharmaceuticals - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2011-09-28T15:10:00+00:00","dateModified":"2026-08-10T17:01:16+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-sells-its-interest-in-johnson-johnson-merck-consumer-pharmaceuticals\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-sells-its-interest-in-johnson-johnson-merck-consumer-pharmaceuticals\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-sells-its-interest-in-johnson-johnson-merck-consumer-pharmaceuticals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Sells Its Interest in Johnson &#038; Johnson-Merck Consumer Pharmaceuticals"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"c25c693f-cf2c-4fe2-9ab6-446a1a480d7f","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742088","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742088\/revisions"}],"predecessor-version":[{"id":3679224,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742088\/revisions\/3679224"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742088"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742088"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}